Epigenetic modulation of BRCA‐1 and MGMT genes, and histones H4 and H3 are associated with breast tumors. Issue 8 (2nd April 2019)

• Record Type: Journal Article
• Authors: Paydar, Parisa; Asadikaram, Gholamreza; Nejad, Hamid Zeynali; Akbari, Hamed; Abolhassani, Moslem; Moazed, Vahid; Nematollahi, Mohammad Hadi; Ebrahimi, Ghasem; Fallah, Hossein
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 8(2019)
• Page Start: 13726
• Page End: 13736
• Publication Date: 2019-04-02
• Subjects: breast cancer -- breast tumor -- epigenetic -- histone modification -- promoter methylation -- tumor suppressor; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.28645
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Aberrant patterns in promoter methylation of tumor‐suppressor genes and posttranslational modifications of histone proteins are considered as major features of malignancy. In this study, we aimed to investigate promoter methylation of three tumor‐suppressor genes ( BRCA‐1, MGMT, and P16 ) and three histone marks (H3K9ac, H3K18ac, and H4K20me3) in patients with breast tumors. This case‐control study included 27 patients with malignant breast tumors (MBT) and 31 patients with benign breast tumors (BBT). The methylation‐specific PCR was used for determining promoter methylation of BRCA‐1, MGMT, and P16 genes. Western blot analysis was performed to detect histone lysine acetylation (H3K9ac and H3K18ac) and lysine methylation (H4K20me3). BRCA‐1 promoter methylation was detected in 44.4% of the MBT whereas this alteration was found in 9.7% of BBT ( P = 0.005). The Kaplan‐Meier analysis indicated that hypermethylation in BRCA‐1 promoter was significantly associated with poor overall survival of patients with breast cancer ( P = 0.039). MGMT promoter methylation was identified in 18.5% of MBT and 0.0% of the BBT ( P = 0.01). The frequency of P16 promoter methylation was 25.8% in BBT and 11.1% in MBT ( P = 0.12). As compared with BBT, MBT samples displayed the aberrant patterns of histones marks with hypomethylation of H4K20 and hypoacetylation of H3K18 ( P = 0.03 and P = 0.04, respectively). There was a negative significant correlation between H3K9ac levels and tumor size in MBT group ( r = −0.672; P = 0.008). The present findings suggest that promoter hypermethylation of MGMT and BRCA‐1 genes along with alterations in H3K18ac and H4K20me3 levels may have prognostic values in patients with breast cancer. Moreover, the detection of these epigenetic modifications in breast tumors could be helpful in finding new methods for breast cancer therapy.